<p>北卡羅來納州夏洛特，2025 年 12 月 23 日（GLOBE NEWSWIRE）——Prenetics Global Limited（納斯達克：PRE）（“Prenetics” 或 “公司”），一家領先的健康科學公司及 IM8 高端健康與長壽品牌的母公司，今天宣佈已與持有約 83.4% 已發行 A 類和 B 類認股權證的持有人達成認股權證交換協議，協議需滿足慣常的成交條件，旨在簡化公司的資本結構並大幅減少未來潛在的稀釋。</p>
<p>該認股權證交換計劃是基於投資者反饋並在與幾位公司最大機構股東的討論後製定的，這些股東對將傳統認股權證工具整合為更清晰的資本結構表示了強烈支持。</p>
<p><strong>背景與參與</strong></p>
<p>在公司 2025 年 10 月的融資中，發行了 2,722,642 股 A 類普通股，每股 A 類普通股對應發行一份 A 類認股權證和一份 B 類認股權證，共計 5,445,284 份認股權證。</p>
<p>截至本公告之日，公司已簽署的交換協議涵蓋了 5,445,284 份 A 類和 B 類認股權證中的 4,539,722 份，參與比例約為 83.4%。</p>
<p><strong>認股權證交換摘要</strong></p>
<p>根據交換協議：</p>
<ul>
<li>一（1）份 A 類認股權證和一（1）份 B 類認股權證，行使價格分別為 24.12 美元和 32.16 美元，每份認股權證的有效期為五年，已被交換為</li>
<li>一（1）份新的 C 類認股權證，其：
<ul>
<li>A 類普通股的行使價格為 18.00 美元，</li>
<li>自 F-3 表格註冊聲明生效之日起有效期為兩年，該註冊聲明用於註冊因行使 C 類認股權證而可發行的股份的轉售，</li>
<li>具有標準的強制贖回（回購）條款。</li>
</ul>
</li>
</ul>
<p>公司僅在 F-3 表格註冊聲明生效後，且僅在公司 A 類普通股連續十（10）個交易日的交易價格達到或超過行使價格的 120%（即 21.60 美元）時，方可行使其強制贖回權。</p>
<p>認股權證持有人自願參與此次交換，所有符合條件的認股權證持有人均獲得相同的條款。</p>
<p><strong>對資本結構的影響</strong></p>
<p>根據交換協議，預計公司約 4.54 百萬份已發行的 A 類和 B 類認股權證將被交換為約 2.27 百萬份 C 類認股權證。</p>
<p>在此次交換後，預計 A 類、B 類和 C 類認股權證的總數將約為 3.18 百萬份，較 2025 年 10 月融資輪中發行的 A 類和 B 類認股權證數量減少約 42.0%，如果所有 A 類和 B 類認股權證持有人全部參與，減少幅度可達 50%。</p>
<p>公司認為，這一減少顯著改善了其長期稀釋狀況，降低了認股權證的過剩，並增強了其普通股的投資吸引力。公司並未因任何融資交易而進行此次認股權證交換，且在可預見的未來沒有進行任何股權或股權相關融資的計劃。</p>
<p><strong>戰略理由與好處</strong></p>
<p>公司認為，此次認股權證交換為公司及其股東帶來了幾項重要好處，包括：</p>
<ul>
<li>A 類和 B 類認股權證數量減少高達 50%，顯著降低長期稀釋風險</li>
<li>大幅消除兩類深度虛值的傳統認股權證，減少公司股份因 A 類和 B 類認股權證而產生的過剩，降低幅度可達 50%</li>
<li>簡化為單一統一的認股權證類別，提高透明度和機構投資吸引力</li>
<li>與股東的改善對齊，提供更現實和可實現的認股權證贖回路徑</li>
</ul>
<p>公司指出，其最大的機構投資者均參與了此次交換，反映出對修訂結構及其長期利益的強烈信心。</p>
<p><strong>關於 Prenetics</strong></p>
<p>Prenetics（納斯達克：PRE）是一家領先的健康科學公司，通過 IM8——其與大衞·貝克漢姆共同創立的旗艦消費品牌，重新定義健康與長壽的未來，並由世界排名第一的網球選手阿麗娜·薩巴倫卡支持。IM8 在補充劑行業歷史上實現了最快的增長軌跡，在推出 11 個月內達到了超過 1 億美元的年經常性收入，甚至超過了領先的人工智能初創公司。</p>
<p><strong>關於 IM8</strong></p>
<p>IM8 是高端核心營養的巔峯之作，由大衞·貝克漢姆作為共同創始人，與一支由醫療專業人士、學術界和太空科學領域的精英科學家組成的團隊合作而成。IM8 結合尖端科學與自然中最有效的成分，提供一種全面的、科學支持的健康方法，使您能夠過上最充實的生活。IM8 的旗艦產品 “每日終極必需品” 是一種全能粉末補充劑，旨在替代 16 種不同的補充劑，口感美味，並獲得 NSF 運動認證，非轉基因，素食，無常見過敏原，不含人工香料、色素或甜味劑。IM8 是 Prenetics（納斯達克：PRE）的子公司，致力於推動消費者健康。欲瞭解更多關於 IM8 的信息，請訪問 www.IM8health.com。</p>
<p><strong>投資者關係聯繫方式：</strong></p>
<p>investors@prenetics.com</p>
<p>PRE@mzgroup.us</p>
<p>Angela Cheung</p>
<p>投資者關係 / 企業融資</p>
<p>angela.hm.cheung@prenetics.com</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含前瞻性聲明。這些聲明是在 1995 年美國《私人證券訴訟改革法案》的 “安全港” 條款下作出的。非歷史事實的聲明，包括關於公司的目標、指標、預測、展望、信念、期望、戰略、計劃、管理層對公司未來運營的目標以及增長機會的聲明，均為前瞻性聲明。我們的指引（包括認股權證結構、數字和時間表）反映了管理層截至本發佈日的當前估計和假設，受到重大風險和不確定性的影響，並不保證未來的表現。實際結果可能會有重大差異。在某些情況下，前瞻性聲明可以通過 “可能”、“將”、“期望”、“預期”、“目標”、“旨在”、“估計”、“打算”、“計劃”、“相信”、“潛在”、“繼續”、“可能會”、“指引”、“展望”、“預測” 或其他類似表達來識別。前瞻性聲明基於估計和預測，反映了公司的觀點、假設、期望和意見，這些都涉及固有的風險和不確定性，因此不應被視為未來結果的必然指示。多種因素可能導致實際結果與任何前瞻性聲明中包含的內容有重大差異，包括但不限於超出公司控制的因素，這些因素阻止了交換協議的完成和最終實現。除了上述因素外，您還應仔細考慮公司最近註冊聲明和其中的招股説明書以及公司不時向美國證券交易委員會提交的其他文件中描述的其他風險和不確定性。除非另有説明，本新聞稿中提供的所有信息均截至本新聞稿日期，公司不承擔更新該信息的任何義務，除非適用法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qVTVOaU0zTXpNME56VXpJekl5TWpRd09UWT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qVTVOaU0zTXpNME56VXpJekl5TWpRd09UWT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2NmZTY2NDItYTA2OC00OWZlLTg2MzMtNmM4OTM1YjhhMzQxLTEyMzU2NDktMjAyNS0xMi0yMy1lbg==/tiny/Prenetics-Global-Limited.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2NmZTY2NDItYTA2OC00OWZlLTg2MzMtNmM4OTM1YjhhMzQxLTEyMzU2NDktMjAyNS0xMi0yMy1lbg==/tiny/Prenetics-Global-Limited.png"/></p>

<p>Prenetics Global Limited 宣佈與持有 83.4% A 類和 B 類認股權證的投資者達成認股權證交換協議，旨在簡化其資本結構並減少未來的稀釋。此次交換涉及將 A 類和 B 類認股權證換為新的 C 類認股權證，後者具有更低的行使價格和兩年的有效期。此舉預計將使未到期的認股權證減少多達 50%，改善長期稀釋狀況並增強股票的投資吸引力。此次交換反映了投資者對 Prenetics 修訂結構的強烈支持和信心</p>

<p>CHARLOTTE, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that it has entered into warrant exchange agreements, subject to customary closing conditions, with holders representing approximately 83.4% of its outstanding Class A and Class B warrants, pursuant to a voluntary warrant exchange program designed to simplify the Company’s capital structure and materially reduce potential future dilution.</p>
<div class="lb-trans"><p>北卡羅來納州夏洛特，2025 年 12 月 23 日（GLOBE NEWSWIRE）——Prenetics Global Limited（納斯達克：PRE）（“Prenetics” 或 “公司”），一家領先的健康科學公司及 IM8 高端健康與長壽品牌的母公司，今天宣佈已與持有約 83.4% 已發行 A 類和 B 類認股權證的持有人達成認股權證交換協議，協議需滿足慣常的成交條件，旨在簡化公司的資本結構並大幅減少未來潛在的稀釋。</p>
</div><p>The warrant exchange program was developed based on investor feedback and following discussions with several of the Company’s largest institutional shareholders, who expressed strong support for consolidating legacy warrant instruments into a cleaner capital structure.</p>
<div class="lb-trans"><p>該認股權證交換計劃是基於投資者反饋並在與幾位公司最大機構股東的討論後製定的，這些股東對將傳統認股權證工具整合為更清晰的資本結構表示了強烈支持。</p>
</div><p><strong>Background and Participation</strong></p>
<div class="lb-trans"><p><strong>背景與參與</strong></p>
</div><p>In connection with the Company’s prior financing in October 2025, 2,722,642 Class A ordinary shares were issued, with one Class A warrant and one Class B warrant issued for each such Class A ordinary share, for a total of 5,445,284 warrants.</p>
<div class="lb-trans"><p>在公司 2025 年 10 月的融資中，發行了 2,722,642 股 A 類普通股，每股 A 類普通股對應發行一份 A 類認股權證和一份 B 類認股權證，共計 5,445,284 份認股權證。</p>
</div><p>As of the date of this announcement, the Company has entered into exchange agreements covering 4,539,722 of the 5,445,284 aggregate Class A and Class B warrants, representing approximately 83.4% participation.</p>
<div class="lb-trans"><p>截至本公告之日，公司已簽署的交換協議涵蓋了 5,445,284 份 A 類和 B 類認股權證中的 4,539,722 份，參與比例約為 83.4%。</p>
</div><p><strong>Summary of the Warrant Exchange</strong></p>
<div class="lb-trans"><p><strong>認股權證交換摘要</strong></p>
</div><p>Under the exchange agreements:</p>
<div class="lb-trans"><p>根據交換協議：</p>
</div><ul>
<li>One (1) Class A warrant and one (1) Class B warrant with exercise prices of $24.12 and $32.16, respectively, each with a five-year term have been exchanged for</li>
<li>One (1) new Class C warrant with:
<ul>
<li>an exercise price of $18.00 per Class A ordinary share,</li>
<li>a two-year term commencing upon the effectiveness of a registration statement on Form F-3 registering the resale of the shares issuable upon exercise of the Class C warrants, and</li>
<li>a standard forced-redemption (call) feature.</li>
</ul>
</li>
</ul>
<div class="lb-trans"><ul>
<li>一（1）份 A 類認股權證和一（1）份 B 類認股權證，行使價格分別為 24.12 美元和 32.16 美元，每份認股權證的有效期為五年，已被交換為</li>
<li>一（1）份新的 C 類認股權證，其：
<ul>
<li>A 類普通股的行使價格為 18.00 美元，</li>
<li>自 F-3 表格註冊聲明生效之日起有效期為兩年，該註冊聲明用於註冊因行使 C 類認股權證而可發行的股份的轉售，</li>
<li>具有標準的強制贖回（回購）條款。</li>
</ul>
</li>
</ul>
</div><p>The Company may exercise its forced-redemption right only after the registration statement on Form F-3 registering the resale of the shares issuable upon exercise of the Class C warrants is declared effective and only if the Company’s Class A ordinary shares trade at or above 120% of the exercise price (i.e., $21.60) for ten (10) consecutive trading days.</p>
<div class="lb-trans"><p>公司僅在 F-3 表格註冊聲明生效後，且僅在公司 A 類普通股連續十（10）個交易日的交易價格達到或超過行使價格的 120%（即 21.60 美元）時，方可行使其強制贖回權。</p>
</div><p>Warrant holders participated in the exchange on a voluntary basis, and identical terms were offered to all eligible warrant holders.</p>
<div class="lb-trans"><p>認股權證持有人自願參與此次交換，所有符合條件的認股權證持有人均獲得相同的條款。</p>
</div><p><strong>Impact on Capital Structure</strong></p>
<div class="lb-trans"><p><strong>對資本結構的影響</strong></p>
</div><p>Based on the exchange agreements, a total of approximately 4.54 million in aggregate of the Company’s outstanding Class A warrants and Class B warrants is expected to be exchanged for approximately 2.27 million Class C warrants.</p>
<div class="lb-trans"><p>根據交換協議，預計公司約 4.54 百萬份已發行的 A 類和 B 類認股權證將被交換為約 2.27 百萬份 C 類認股權證。</p>
</div><p>After such exchange, the total number of outstanding Class A warrants, Class B warrants and Class C warrants is expected to be approximately 3.18 million in aggregate, representing a reduction of approximately 42.0% from the number of Class A and Class B warrants issued in the October 2025 financing round, and further up to 50% assuming participation in full by all holders of Class A warrants and Class B warrants.</p>
<div class="lb-trans"><p>在此次交換後，預計 A 類、B 類和 C 類認股權證的總數將約為 3.18 百萬份，較 2025 年 10 月融資輪中發行的 A 類和 B 類認股權證數量減少約 42.0%，如果所有 A 類和 B 類認股權證持有人全部參與，減少幅度可達 50%。</p>
</div><p>The Company believes this reduction materially improves its long-term dilution profile, reduces warrant overhang, and enhances the investability of its ordinary shares. The Company is not undertaking this warrant exchange in connection with any financing transaction and has no plans to conduct any equity or equity-linked capital raise in the foreseeable future.</p>
<div class="lb-trans"><p>公司認為，這一減少顯著改善了其長期稀釋狀況，降低了認股權證的過剩，並增強了其普通股的投資吸引力。公司並未因任何融資交易而進行此次認股權證交換，且在可預見的未來沒有進行任何股權或股權相關融資的計劃。</p>
</div><p><strong>Strategic Rationale and Benefits</strong></p>
<div class="lb-trans"><p><strong>戰略理由與好處</strong></p>
</div><p>The Company believes this warrant exchange delivers several meaningful benefits to the Company and its shareholders, including:</p>
<div class="lb-trans"><p>公司認為，此次認股權證交換為公司及其股東帶來了幾項重要好處，包括：</p>
</div><ul>
<li>Up to 50% reduction from the number of outstanding Class A warrants and Class B warrants, materially lowering long-term dilution risk</li>
<li>Substantial elimination of two deep out-of-the-money legacy classes of warrants, reducing up to 50% of the overhang on the Company’s shares that resulted from the Class A warrants and Class B warrants</li>
<li>Simplification in favor of a single, unified class of warrants, improving transparency and institutional investability</li>
<li>Improved alignment with shareholders, by providing a more realistic and attainable path to warrant redemption</li>
</ul>
<div class="lb-trans"><ul>
<li>A 類和 B 類認股權證數量減少高達 50%，顯著降低長期稀釋風險</li>
<li>大幅消除兩類深度虛值的傳統認股權證，減少公司股份因 A 類和 B 類認股權證而產生的過剩，降低幅度可達 50%</li>
<li>簡化為單一統一的認股權證類別，提高透明度和機構投資吸引力</li>
<li>與股東的改善對齊，提供更現實和可實現的認股權證贖回路徑</li>
</ul>
</div><p>The Company noted that its largest institutional investors, each with significant long-term investments, have participated in the exchange, reflecting strong confidence in the revised structure and its long-term benefits.</p>
<div class="lb-trans"><p>公司指出，其最大的機構投資者均參與了此次交換，反映出對修訂結構及其長期利益的強烈信心。</p>
</div><p><strong>About Prenetics</strong></p>
<div class="lb-trans"><p><strong>關於 Prenetics</strong></p>
</div><p>Prenetics (NASDAQ: PRE) is a leading health sciences company redefining the future of health and longevity through IM8 — its flagship consumer brand co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka. IM8 has achieved the fastest growth trajectory in supplement industry history, reaching $100 million+ in ARR within 11 months of launch, outpacing even leading AI startups.</p>
<div class="lb-trans"><p>Prenetics（納斯達克：PRE）是一家領先的健康科學公司，通過 IM8——其與大衞·貝克漢姆共同創立的旗艦消費品牌，重新定義健康與長壽的未來，並由世界排名第一的網球選手阿麗娜·薩巴倫卡支持。IM8 在補充劑行業歷史上實現了最快的增長軌跡，在推出 11 個月內達到了超過 1 億美元的年經常性收入，甚至超過了領先的人工智能初創公司。</p>
</div><p><strong>About IM8</strong></p>
<div class="lb-trans"><p><strong>關於 IM8</strong></p>
</div><p>IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.</p>
<div class="lb-trans"><p>IM8 是高端核心營養的巔峯之作，由大衞·貝克漢姆作為共同創始人，與一支由醫療專業人士、學術界和太空科學領域的精英科學家組成的團隊合作而成。IM8 結合尖端科學與自然中最有效的成分，提供一種全面的、科學支持的健康方法，使您能夠過上最充實的生活。IM8 的旗艦產品 “每日終極必需品” 是一種全能粉末補充劑，旨在替代 16 種不同的補充劑，口感美味，並獲得 NSF 運動認證，非轉基因，素食，無常見過敏原，不含人工香料、色素或甜味劑。IM8 是 Prenetics（納斯達克：PRE）的子公司，致力於推動消費者健康。欲瞭解更多關於 IM8 的信息，請訪問 www.IM8health.com。</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投資者關係聯繫方式：</strong></p>
</div><p>investors@prenetics.com</p>
<div class="lb-trans"><p>investors@prenetics.com</p>
</div><p>PRE@mzgroup.us</p>
<div class="lb-trans"><p>PRE@mzgroup.us</p>
</div><p>Angela Cheung</p>
<div class="lb-trans"><p>Angela Cheung</p>
</div><p>Investor Relations / Corporate Finance</p>
<div class="lb-trans"><p>投資者關係 / 企業融資</p>
</div><p>angela.hm.cheung@prenetics.com</p>
<div class="lb-trans"><p>angela.hm.cheung@prenetics.com</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance (including warrant structure, numbers and timeline) reflects management’s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to factors beyond the Company’s control that prevent the closing and final consummation of the exchange agreements. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.</p>
<div class="lb-trans"><p>本新聞稿包含前瞻性聲明。這些聲明是在 1995 年美國《私人證券訴訟改革法案》的 “安全港” 條款下作出的。非歷史事實的聲明，包括關於公司的目標、指標、預測、展望、信念、期望、戰略、計劃、管理層對公司未來運營的目標以及增長機會的聲明，均為前瞻性聲明。我們的指引（包括認股權證結構、數字和時間表）反映了管理層截至本發佈日的當前估計和假設，受到重大風險和不確定性的影響，並不保證未來的表現。實際結果可能會有重大差異。在某些情況下，前瞻性聲明可以通過 “可能”、“將”、“期望”、“預期”、“目標”、“旨在”、“估計”、“打算”、“計劃”、“相信”、“潛在”、“繼續”、“可能會”、“指引”、“展望”、“預測” 或其他類似表達來識別。前瞻性聲明基於估計和預測，反映了公司的觀點、假設、期望和意見，這些都涉及固有的風險和不確定性，因此不應被視為未來結果的必然指示。多種因素可能導致實際結果與任何前瞻性聲明中包含的內容有重大差異，包括但不限於超出公司控制的因素，這些因素阻止了交換協議的完成和最終實現。除了上述因素外，您還應仔細考慮公司最近註冊聲明和其中的招股説明書以及公司不時向美國證券交易委員會提交的其他文件中描述的其他風險和不確定性。除非另有説明，本新聞稿中提供的所有信息均截至本新聞稿日期，公司不承擔更新該信息的任何義務，除非適用法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qVTVOaU0zTXpNME56VXpJekl5TWpRd09UWT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjU5NiM3MzM0NzUzIzIyMjQwOTY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2NmZTY2NDItYTA2OC00OWZlLTg2MzMtNmM4OTM1YjhhMzQxLTEyMzU2NDktMjAyNS0xMi0yMy1lbg==/tiny/Prenetics-Global-Limited.png" alt="" original-src="https://ml.globenewswire.com/media/M2NmZTY2NDItYTA2OC00OWZlLTg2MzMtNmM4OTM1YjhhMzQxLTEyMzU2NDktMjAyNS0xMi0yMy1lbg==/tiny/Prenetics-Global-Limited.png"/></p>

Prenetics 與認股權證持有人簽署交換協議，以加強其資本結構 | PRE 股票新聞